ERBB2 and breast carcinoma: To improve clinical prospects of GDEPT with HchrR6 mRNA for HER2+ breast cancer treatment, a follow-up study administered EVs both loaded with functional HchrR6 mRNA and labeled with anti-HER2+ antibodies with tretazicar, a clinically tested prodrug with a well-established safe dose, in addition to CNOB, and observed growth-arrest of HER2+ human breast cancer tumors 119.